A role for IRF4 in the development of CLL

Blood

Volumn 122, Issue 16, 2013, Pages 2848-2855

  Shukla, Vipul ^a   Ma, Shibin ^a   Hardy, Richard R ^b   Joshi, Shantaram S ^a   Lu, Runqing ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD19 ANTIGEN; CD1D ANTIGEN; CD23 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; IMMUNOGLOBULIN D; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; INTERFERON REGULATORY FACTOR 4; MICRORNA 15A; MICRORNA 16; PROTEIN BCL 2; PROTEIN BCL XL; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4; MCL1 PROTEIN, MOUSE; MYELOID LEUKEMIA FACTOR 1;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMOGENESIS; LYMPHADENOPATHY; MONOCLONAL B CELL LYMPHOCYTOSIS; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPLENOMEGALY; ANIMAL; C57BL MOUSE; CELL TRANSPLANTATION; CROSS BREEDING; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; METABOLISM; MUTATION; SPLEEN; TRANSGENIC MOUSE;

ALLELES; ANIMALS; APOPTOSIS; CELL TRANSPLANTATION; CROSSES, GENETIC; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; INTERFERON REGULATORY FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PHENOTYPE; SPLEEN;

EID: 84888211403     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-492769     Document Type: Article

References (47)

1. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008;26: 535-584.
2. De Silva NS, Simonetti G, Heise N, Klein U. The diverse roles of IRF4 in late germinal center B-cell differentiation. Immunol Rev. 2012;247(1):73-92.
3. Lu R. Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol. 2008;29(10): 487-492.
4. Ma S, Pathak S, Mandal M, Trinh L, Clark MR, Lu R. Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Mol Cell Biol. 2010;30(17):4149-4158.
5. Ma S, Pathak S, Trinh L, Lu R. Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B-cell receptor and promote cell-cycle withdrawal in pre-B-cell development. Blood. 2008;111(3): 1396-1403.
6. Ma S, Turetsky A, Trinh L, Lu R. IFN regulatory factor 4 and 8 promote Ig light chain kappa locus activation in pre-B cell development. J Immunol. 2006;177(11):7898-7904.
7. Klein U, Casola S, Cattoretti G, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol. 2006; 7(7):773-782.
8. Saito M, Gao J, Basso K, et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell. 2007; 12(3):280-292.
9. Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity. 2006;25(2):225-236.
10. Acquaviva J, Chen X, Ren R. IRF-4 functions as a tumor suppressor in early B-cell development. Blood. 2008;112(9):3798-3806.
11. Pathak S, Ma S, Trinh L, et al. IRF4 is a suppressor of c-Myc induced B cell leukemia. PLoS ONE. 2011;6(7):e22628.
12. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008; 454(7201):226-231.
13. Kipps TJ. Immunobiology of chronic lymphocytic leukemia. Curr Opin Hematol. 2003;10(4): 312-318.
14. Gaidano G, Foà R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012;122(10):3432-3438.
15. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2008;40(10): 1204-1210.
16. Crowther-Swanepoel D, Broderick P, Ma Y, et al. Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus. Hum Mol Genet. 2010;19(9):1840-1845.
17. Chang CC, Lorek J, Sabath DE, et al. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood. 2002;100(13):4671-4675.
18. Havelange V, Pekarsky Y, Nakamura T, et al. IRF4 mutations in chronic lymphocytic leukemia. Blood. 2011;118(10):2827-2829.
19. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood. 2011;117(6):1781-1791.
20. Hardy RR. B-1 B cell development. J Immunol. 2006;177(5):2749-2754.
21. Hardy RR, Wei CJ, Hayakawa K. Selection during development of VH111 B cells: a model for natural autoantibody-producing CD51 B cells. Immunol Rev. 2004;197:60-74.
22. Wen L, Shinton SA, Hardy RR, Hayakawa K. Association of B-1 B cells with follicular dendritic cells in spleen. J Immunol. 2005;174(11): 6918-6926.
23. Mittrücker HW, Matsuyama T, Grossman A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997;275(5299):540-543.
24. Enzler T, Kater AP, Zhang W, et al. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood. 2009;114(20):4469-4476.
25. Herling M, Patel KA, Khalili J, et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia. 2006;20(2):280-285.
26. Yan XJ, Albesiano E, Zanesi N, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2006;103(31):11713-11718.
27. Allan JM, Sunter NJ, Bailey JR, et al. Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. Leukemia. 2010;24(4):877-881.
28. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367-3375.
29. Bagnara D, Kaufman MS, Calissano C, et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood. 2011; 117(20):5463-5472.
30. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115(3):755-764.
31. Chiorazzi N, Hatzi K, Albesiano E. B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens. Ann N Y Acad Sci. 2005;1062:1-12.
32. Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med. 2008;264(6):549-562.
33. Chen SS, Batliwalla F, Holodick NE, et al. Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling. Proc Natl Acad Sci U S A. 2013;110(16):E1500-E1507.
34. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 2008;111(2): 846-855.
35. Pepper C, Lin TT, Pratt G, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood. 2008;112(9): 3807-3817.
36. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102(39):13944-13949.
37. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17(1):28-40.
38. Liu J, Chen G, Feng L, et al. Loss of p53 and altered miR15-a/16-1 MCL-1 pathway in CLL: insights from TCL1-Tg:p53-/- mouse model and primary human leukemia cells [published online ahead of print April 23, 2013]. Leukemia.
39. Laine J, Künstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell. 2000;6(2):395-407.
40. Pekarsky Y, Koval A, Hallas C, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci U S A. 2000;97(7):3028-3033.
41. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A. 2002;99(10):6955-6960.
42. Lia M, Carette A, Tang H, et al. Functional dissection of the chromosome 13q14 tumorsuppressor locus using transgenic mouse lines. Blood. 2012;119(13):2981-2990.
43. Bhat NM, Bieber MM, Spellerberg MB, Stevenson FK, Teng NN. Recognition of auto- and exoantigens by V4-34 gene encoded antibodies. Scand J Immunol. 2000;51(2):134-140.
44. Cabiedes J, Cabral AR, López-Mendoza AT, Cordero-Esperón HA, Huerta MT, Alarcón-Segovia D. Characterization of anti-phosphatidylcholine polyreactive natural autoantibodies from normal human subjects. J Autoimmun. 2002;18(2):181-190.
45. Guchhait P, López JA, Thiagarajan P. Characterization of autoantibodies against sulfatide from a V-gene phage-display library derived from patients with systemic lupus erythematosus. J Immunol Methods. 2004; 295(1-2):129-137.
46. Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012;44(11):1236-1242.
47. Martín-Subero JI, López-Otín C, Campo E. Genetic and epigenetic basis of chronic lymphocytic leukemia. Curr Opin Hematol. 2013; 20(4):362-368.